Plain-English translation of NCT06956482 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether N-acetylcysteine, combined with a steroid called , can help people with severe alcohol-related liver disease. Currently, alone is the standard treatment, but it doesn't work for everyone. Researchers want to see if the medication can improve survival and liver function, especially when treatment is extended beyond the current one month.
About 30% of patients don't respond well to steroid treatment alone, and many people still have liver problems even after the standard one-month treatment ends. This trial is trying to find a better approach by testing whether the medication combined with longer treatment can help more patients recover.
You likely qualify if…
You likely don't qualify if…
You would receive (a steroid) for 30 days as the standard treatment. During the first 5 days, you would also receive either the medication or a placebo. After the first month, depending on which study group you're assigned to, you would receive either a placebo or continue with tapering doses of for another 30 days. You'll have regular medical visits and tests to monitor your liver function and overall health throughout the trial.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France